COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Cory M. Johannessen(Novartis (China)), Levi A. Garraway(Broad Institute), Robert Schlegel(Pathways Behavioral Services), Jesse S. Boehm(Massachusetts Institute of Technology), Keith T. Flaherty(Cancer Research Center), Giordano Caponigro(Novartis (Switzerland)), Thomas M. Roberts(Dana-Farber Cancer Institute), Alexandria P. Cogdill(University of Pennsylvania), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Marc Vidal(Harvard University), Jean J. Zhao(Harvard University), Sapana Thomas(Broad Institute), Jordi Barretina(Broad Institute), Kourosh Salehi‐Ashtiani(New York University Abu Dhabi), William R. Sellers(Broad Institute), Christopher J. Wilson, William C. Hahn(Broad Institute), Xiaoping Yang(Broad Institute), Nicolas Stransky(Broad Institute), Jennifer L. Harris(Genomics Institute of the Novartis Research Foundation), Ryan R. Murray(Harvard University), David E. Hill(Harvard University), Leslie Wardwell(Harvard University), Vic E. Myer, Haley Hieronymus(Broad Institute), David E. Root(Broad Institute), Reinhard Dummer(University Hospital of Zurich), So Young Kim(Chungbuk National University), Sung Joon Kim(Seoul National University), Ozan Alkan(Gümüşhane University), Laura A. Johnson(Broad Institute), Todd R. Golub(Broad Institute), Peter M. Finan, Barbara L. Weber
Nature
November 24, 2010
Cited by 1,448


Related Papers